Metabolite profiling identifies anandamide as a biomarker of nonalcoholic steatohepatitis
Metabolite profiling identifies anandamide as a biomarker of nonalcoholic steatohepatitis
复制标题
DOI：
10.1172/jci.insight.92989
复制
发表时间：
2017-05-04
期刊：
影响因子：
8
通讯作者：
Gerszten, Robert E.
中科院分区：
文献类型：
--
作者：
Kimberly, W. Taylor;O'Sullivan, John F.;Gerszten, Robert E.
代谢物-表型关联的发现可能会突出疾病状态下改变的候选生物标志物和代谢途径。我们试图利用液相色谱-串联质谱法来鉴定与肥胖及其主要并发症之一非酒精性脂肪肝（NAFLD）相关的新型代谢物。在弗雷明汉心脏研究第 3 代 (FHS Gen 3) 的 997 名个体中，我们发现了大麻素 (AEA) 与 BMI 之间的关联。进一步检查发现 AEA 与放射学肝脂肪变性相关。在组织学定义的 NAFLD 队列中，AEA 与 NAFLD 严重程度、非酒精性脂肪性肝炎和纤维化的存在相关。这些数据强调 AEA 作为心脏代谢疾病和 NAFLD 严重程度之间联系的标志物。
The discovery of metabolite-phenotype associations may highlight candidate biomarkers and metabolic pathways altered in disease states. We sought to identify novel metabolites associated with obesity and one of its major complications, nonalcoholic fatty liver disease (NAFLD), using a liquid chromatography-tandem mass spectrometry method. In 997 individuals in Framingham Heart Study Generation 3 (FHS Gen 3), we identified an association between anandamide (AEA) and BMI. Further examination revealed that AEA was associated with radiographic hepatic steatosis. In a histologically defined NAFLD cohort, AEA was associated with NAFLD severity, the presence of nonalcoholic steatohepatitis, and fibrosis. These data highlight AEA as a marker linking cardiometabolic disease and NAFLD severity.